FDA Extends Novartis Drug Review
13th Nov 2006, 21:10 GMT
Novartis said the FDA will take three months longer than expected to decide on the approval of its experimental diabetes drug Galvus. The delay presents a short-term advantage for rival Merck.
FDA Extends Novartis Drug Review related news:
- FDA Review on Novartis Galvus Extended — Government/ Industry Regulation News from StratCenter.com
- FDA Decision on Novartis Drug Is Delayed — WSJ.com: What's News Europe
- Novartis announces three-month extension of US regulatory review for Galvus® to assess recently available clinical data — WebWire - Recent Headlines
- Novartis Diebetes Drug Gets FDA Setback — StratWire - Business of Healthcare NewsFeed
- Novartis diabetes drug faces three month delay — Pharmaceutical Business Review Latest News
- U.S. delays Novartis diabetes drug — Marketplace by Bloomberg - International Herald Tribune
- Alexion gets fast-track FDA review for drug Soliris — bizjournals.com Health Care:Pharmaceuticals headlines
- FDA Urges Caution on Flu Drug — WSJ.com: What's News US
- FDA Suggests New Tamiflu Warning — WSJ.com: What's News US
- Alexion Gets Priority Review on Soliris — Bio-Technology News from StratCenter.com
Latest news from WSJ.com: What's News Europe:
- Deutsche Telekom CEO Resigns
- European Shares Gain Ground
- Arcelor Mittal Says Dofasco Sale Is Thwarted
- U.K. Life-Insurance Market May Shrink
- Two Italian Banks Discuss Merger
- European Shares Gain Ground
- Qualcomm, Nokia Deal Is Unlikely
- BPU Board Backs Purchase of Rival
- Marshall Wace Plans Hedge-Fund IPO
- FDA Decision on Novartis Drug Is Delayed